Problems of long survival following surgery in patients with NonBNonC-HCC: Comparison with HBV and HCV related-HCC

Journal of Cancer

Volumn 6, Issue 5, 2015, Pages 438-447

  Hiwatashi, Kiyokazu ^a   Ueno, Shinichi ^a   Sakoda, Masahiko ^a   Iino, Satoshi ^a   Minami, Koji ^a   Yamasaki, Yoichi ^a   Okubo, Keishi ^a   Noda, Masahiro ^a   Kurahara, Hiroshi ^a   Mataki, Yuko ^a   Maemura, Kosei ^a   Shinchi, Hiroyuki ^b   Natsugoe, Shoji ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

HBs antigen; HCV antibody; Hepatocellular carcinoma; NBNC HCC; Surgical resection

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY;

ABLATION THERAPY; AGED; ARTICLE; BODY MASS; CANCER SURVIVAL; CAUSE OF DEATH; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; DIABETES MELLITUS; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; LAPAROSCOPIC SURGERY; LAPAROTOMY; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER HISTOLOGY; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONBNONC LIVER CELL CARCINOMA; OVERALL SURVIVAL; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; SURVIVAL; UNIVARIATE ANALYSIS;

EID: 84930210338     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.10398     Document Type: Article

References (25)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999; 340: 745-50.
2. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999; 19: 271-85.
3. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142: 1264-73.
4. Japan Ministry of Health, Labor and Welfare. Japan Ministry of Health, Labor and Welfare carried out in 2008.2008.
5. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010; 51: 1820-32.
6. N'Kontchou G, Paries J, Htar MT, et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol. 2006; 4: 1062-8.
7. Ikai I, Kudo M, Arii S, et al. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res. 2010; 40: 1043-59.
8. Leslie HS, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours, 7th Edition Union for International Cancer Control. Wiley-Blackwell 2009.
9. Matsumoto K, Yoshimoto J, Sugo H, et al. Relationship between the histological degrees of hepatitis and the postoperative recurrence of hepatocellular carcinoma in patients with hepatitis C. Hepatol Res. 2002; 23: 196-201.
10. Davila JA, Morgan RO, Shaib Y, et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005; 54: 533-9.
11. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004; 126: 460-8.
12. Conlon BA, Beasley JM, Aebersold K, et al. Nutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD). Nutrients. 2013; 5: 4093-114.
13. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011; 34: 274-85.
14. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008; 40: 1461-5.
15. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011; 53: 1883-94.
16. Bellentani S, Scaglioni F, Marino F, et al. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010; 28: 155-61.
17. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000; 894: 1-253.
18. Nishikawa H, Osaki Y, Takeda H, et al. Effect of body mass index on survival after curative therapy for non-B non-C hepatocellular carcinoma. J Gastrointestin Liver Dis. 2013; 22: 173-81.
19. McCurry J. Japan battles with obesity. Lancet. 2007; 369: 451-2.
20. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51: 1972-8.
21. Nishikawa H, Arimoto A, Wakasa T, et al. Comparison of clinical characteristics and survival after surgery in patients with non-B and non-C hepatocellular carcinoma and hepatitis virus-related hepatocellular carcinoma. J Cancer. 2013 4: 502-13.
22. Li T, Qin LX, Gong X, et al. Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection. Cancer. 2013; 119: 126-35.
23. Hotta N, Nakamura J, Iwamoto Y, et al. Causes of death in Japanese diabetics: A questionnaire survey of 18,385 diabetics over a 10-year period. J Diabetes Investig. 2010; 1(1-2): 66-76.
24. Carr Bl, Guerra V, Giannini EG, et al. Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype. Semin Oncol. 2014; 41(2): 252-8.
25. Kinoshita A, Onoda H, Imai N, et al. The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer. 2013; 13: 52.